Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808300 | 0.94 | CYP19A1 (0.46) | CYP19A1SCN5ACACNA1BSLC6A3LMNA | |
| SCHEMBL5089274 | 0.92 | CYP19A1 (0.45) | CYP19A1SCN5ACACNA1BSLC6A3LMNA | |
| SCHEMBL6902789 | 0.92 | CYP19A1 (0.45) | CYP19A1SCN5ACACNA1BSLC6A3LMNA | |
| SCHEMBL3688208 | 0.86 | CYP19A1 (0.44) | CYP19A1SCN5ACACNA1BMAPK1MITF | |
| SCHEMBL6702276 | 0.81 | CYP19A1 (0.49) | CYP19A1HTR2AHRH1MAPK1MITF | |
| SCHEMBL21393419 | 0.81 | AOC3 (0.47) | SLC6A3DRD3LMNA | |
| SCHEMBL6700730 | 0.80 | CYP19A1 (0.49) | CYP19A1SCN5ACACNA1BSLC6A3HTR2A | |
| SCHEMBL904449 | 0.79 | HRH1 (0.60) | CYP19A1SLC6A3HTR2AHRH1CYP3A4 | |
| SCHEMBL3756197 | 0.79 | CACNA1B (0.35) | CACNA1BSLC6A3HTT | |
| SCHEMBL904927 | 0.78 | CYP19A1 (0.47) | CYP19A1SCN5ACACNA1BSLC6A3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4353713-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Kinki University (JP) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260016-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 学校法人近畿大学 | 2022-12-15 | — | — | WO | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5932573-A | Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof | WARNER-LAMBERT COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5767129-A | TREATING CEREBROVASCULAR DISORDERS, PAIN, CEREBRAL ISCHEMIA | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-4918073-A | CALCIUM ANTAGONISTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-17 | — | — | US | disclosed |
| US-4801706-A | ANTIARRHYTHMIA HYPOTENSIVE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0229623-A2 | Diaryl-substituted alkylamines, procedure for their preparation, their application and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-22 | — | — | EP | disclosed |
| US-4590273-A | NEUROLEPTIC HYPOTENSIVE AND ANTIARRHYTHMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | CYP19A1 1036/4885SCN5A 1000/4885CACNA1B 2243/4885 |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1G, CACNA1I, CACNA1H | CYP19A1 4368/4885SCN5A 95/4885CACNA1B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.